Raptor Pharmaceutical has reported positive results from a RP103 (cysteamine bitartrate delayed-release) extension study in which nephropathic cystinosis patients finishing the Phase III trial chose to continue therapy.

A total of 40 patients were examined for white blood cell (WBC) cystine levels, plasma cysteamine levels, estimated glomerular filtration rate (eGFR), quality of life (PedsQL) and use of antacids.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Northwestern University Feinberg School of Medicine kidney diseases head Dr Craig Langman said cystine reduction therapy is effective, but is a lifelong commitment.

"WBC cystine levels were maintained constantly below the therapeutic target in patients with nephropathic cystinosis using RP103 for up to 24 months."

"Even brief delays in daily therapy permit toxic cystine accumulation, exposing tissues to renewed and progressive deterioration," Langman said.

"The currently approved immediate release formulation of cysteamine bitartrate taken every six hours is effective but difficult to use over the long-term."

According to the study data, WBC cystine levels were maintained constantly below the therapeutic target in patients with nephropathic cystinosis using RP103 for up to 24 months.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the company, the total daily dose of RP103 given each 12 hours to achieve optimal WBC cystine levels was on average 72% of the initial immediate release cysteamine bitartrate dose, after 20 month treatment.

Steady eGFR levels signify that the kidney function was conserved throughout the study and patients are able decrease the use of anti-acid medications by almost 50%.

Considerable improvements in all measured quality of life parameters were reported in the extension study.